SCINTOMICS Molecular (att) Applied Theranostics Technologies GmbH
SCINTOMICS is a worldwide active private company providing synthesizers for research and GMP production of innovative and routine radiopharmaceuticals, quality control equipment and corresponding services.
SCINTOMICS GRP synthesizers combine functionality and performance with simplicity and GMP/cGMP-design into one modular and upgradable system. By exploiting ready-to-use GMP kits for cost-efficient fixed-tubing modules or disposable cassette modules, the GRP-series has been especially developed to meet the requirements of routine GMPproduction in a clinical environment. This makes the GRP synthesizer a unique and valuable tool to establish and maintain an optimum work flow and patient care in the daily routine.
In addition, SCINTOMICS offers innovative peptide precursors for radiometallation, such as the first highly specific DOTA-conjugated CXCR4 ligand 68Ga-Pentixafor, the PSMA inhibitors PSMA-HBED-CC and PSMA I&T for imaging and therapy, the first TRAPbased RGD imaging probe 68Ga-Avebetrin, the sst-ligand HA-DOTATATE and other sst-ligands.